This year, Dr. Sam Shapiro underwent total hip arthroplasty. Her journey from being an athlete to suffering from arthritis and chronic joint pain was difficult. Here is her story, complete with post-op insights.
Search results for: hospital
JAK Inhibitors 101
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
FDA Approves Ustekinumab-stba for All Forms & Dosages as Its Reference Product
Ustekinumab-stba (Steqeyma) now has FDA approval for all forms and dosages of its reference product, ustekinumab (Stelara), including a subcutaneous injection to treat pediatric patients with plaque psoriasis or psoriatic arthritis.
Highlights from the European Congress of Internal Medicine
An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.
Rheumatology in China: An American Fellow’s Experience
An American rheumatology fellow explores the differences& similarities between the U.S. & Chinese health systems through a visit toa hospital inHangzhou, China.
Doctoring Differently, Part 2
In part 2 of Dr. Sam Shapiro’s journey, learn how she connected with the rheumatology community to change her career and found a better way to embrace her passions for clinical rheumatology, education and helping patients.
Past ACR President Named a PANLAR Master
This spring, PANLAR designated Mary K. Crow, MD, a Master of Rheumatology. She was honored for her career in research and work extending research opportunities to investigators in Latin America.
Rheumatologists Across Borders
The EULAR/ACR/APLAR Research Exchange Program is an opportunity to learn and exchange ideas within the rheumatology community internationally. Here the program’s most recent participants share their experiences & excitement.
Positive Week 12 Results for Rosnilimab in Patients with RA
Early study results demonstrate that rosnilimab may be safe and effective for patients with rheumatoid arthritis, reducing the signs and symptoms of RA by week 12 and achieving important primary and secondary study end points.
Biosimilar Update: 2025 Brings More FDA Approvals & Interchangeability
Here is a brief recap of the latest FDA-approved biosimilar agents, highlighting their reference products and interchangeability.
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 326
- Next Page »